About us

About us

Developability is a journey that starts at discovery

FairJourney Bio is a full-service antibody CRO: from the first discovery campaign to the IND batch. More than 14 years of experience. 300 scientists. Four locations. One mission: to give every partner the best possible chance of getting a great antibody to the clinic.

Developability is a journey that starts at discovery

FairJourney Bio is a full-service antibody CRO: from the first discovery campaign to the IND batch. More than 14 years of experience. 300 scientists. Four locations. One mission: to give every partner the best possible chance of getting a great antibody to the clinic.

Developability is a journey that starts at discovery

FairJourney Bio is a full-service antibody CRO: from the first discovery campaign to the IND batch. More than 14 years of experience. 300 scientists. Four locations. One mission: to give every partner the best possible chance of getting a great antibody to the clinic.

We built FairJourney Bio to remove those handovers

Discovery, engineering, characterisation, and structural biology sit under one scientific leadership, working from one dataset on one timeline. A liability flagged by characterisation is addressed by engineering inside the same week, not the next contract cycle.

The result is what we set out to deliver from the start: developable leads, not just hits

We built FairJourney Bio to remove those handovers

Discovery, engineering, characterisation, and structural biology sit under one scientific leadership, working from one dataset on one timeline. A liability flagged by characterisation is addressed by engineering inside the same week, not the next contract cycle.

The result is what we set out to deliver from the start: developable leads, not just hits

We built FairJourney Bio to remove those handovers

Discovery, engineering, characterisation, and structural biology sit under one scientific leadership, working from one dataset on one timeline. A liability flagged by characterisation is addressed by engineering inside the same week, not the next contract cycle.

The result is what we set out to deliver from the start: developable leads, not just hits

Where we are  

Three centres of excellence in Europe and the United States, one connected workflow.

Porto, Portugal

Headquarters and discovery. Our largest site, a 170,000 sq ft purpose-built research centre with more than 140 laboratories, opened in 2021. Home to discovery, protein production, characterisation, and programme leadership.

Porto, Portugal

Headquarters and discovery. Our largest site, a 170,000 sq ft purpose-built research centre with more than 140 laboratories, opened in 2021. Home to discovery, protein production, characterisation, and programme leadership.

Cambridge, UK

Engineering and optimisation. Our UK centre of excellence on the Unity Campus, with dedicated Mammalian Display and antibody engineering laboratories, built on more than a decade in one of the world's leading scientific hubs.

Cambridge, UK

Engineering and optimisation. Our UK centre of excellence on the Unity Campus, with dedicated Mammalian Display and antibody engineering laboratories, built on more than a decade in one of the world's leading scientific hubs.

San Diego, USA

Structural biology and Cryo-EM. Our dedicated structural biology hub, home to in-house 300kV Cryo-EM. Epitope mapping, structure-based design, and epitope-based hit discovery, integrated with discovery and engineering rather than outsourced.

San Diego, USA

Structural biology and Cryo-EM. Our dedicated structural biology hub, home to in-house 300kV Cryo-EM. Epitope mapping, structure-based design, and epitope-based hit discovery, integrated with discovery and engineering rather than outsourced.

AMGEN

AMGEN

AMGEN
Astrazeneca

Astrazeneca

Astrazeneca
Bayer

Bayer

Bayer
Bristol Myers Squibb

Bristol Myers Squibb

Bristol Myers Squibb
Genentech

Genentech

Genentech
Johnson & Johnson

Johnson & Johnson

Johnson & Johnson
Lilly

Lilly

Lilly
MSD

MSD

MSD
Takeda

Takeda

Takeda
Regeneron

Regeneron

Regeneron

Partnering With Us

We do not take projects. We take responsibility

More than 250 partners worldwide, from VCs and virtual biotechs to biotech companies, academic institutes, foundations, and pharma companies. Whatever the size of the programme, one team stays accountable from the first target conversation to the IND package.

Dedicated project teams

One scientist owns your programme

Not a rotating team.

Not a project manager between you and the lab.

One scientific lead,  accountable from target to candidate, present in every decision.

Full data transparency

You see everything, in real time

Your data is yours, accessible as it's generated, not summarised in quarterly reports. ​

No black boxes. ​No waiting for milestones to understand what's happening.

Flexible commercial models

Commercial structures built around your capital situation

Fee-for-service for programmes with clear scope. ​Milestone-based or co-ownership structures for capital-efficient innovation. ​

We configure the commercial model to fit the programme, not the other way around.

Western IP and regulatory standards

Your IP is protected under Western jurisdiction — from day one

Every data point generated under EU/US regulatory frameworks. ​

Full audit trail from library  to IND.

Built site by site, capability by capability 

2012

Founded in Porto, Portugal

Since then, we have conquered >250 industry partners

2012

Founded in Porto, Portugal

Since then, we have conquered >250 industry partners

2013

We became profitable

2013

We became profitable

2015

The first large pharma contract was won

>1400programmescompleted, 20 partners assets in clinical trials

2015

The first large pharma contract was won

>1400programmescompleted, 20 partners assets in clinical trials

2016

3,200 m² purpose-built R&D facility

Today, we have EU+US reliable IP frameworks, and three centers of excellence in PT, US and UK

2016

3,200 m² purpose-built R&D facility

Today, we have EU+US reliable IP frameworks, and three centers of excellence in PT, US and UK

2019

Our self-funded expansion begins

Today we are >250 Scientists in Europe and US, >60 PhDs in mAb research

2019

Our self-funded expansion begins

Today we are >250 Scientists in Europe and US, >60 PhDs in mAb research

2020

Iontas joins, adding patented Mammalian Display in Cambridge, UK

2020

Iontas joins, adding patented Mammalian Display in Cambridge, UK

2024

US expansion begins, backed by Partners Group

2024

US expansion begins, backed by Partners Group

2025

Superhuman and Cosmic libraries added

2025

Superhuman and Cosmic libraries added

2026

In-house 300kV Atomic-Level Cryo-EM facilities operational in San Diego

2026

In-house 300kV Atomic-Level Cryo-EM facilities operational in San Diego

Designing a programme around a difficult target? Our scientific team will help you choose the right discovery and engineering strategy for your molecule, before you commit.

Get in touch

Designing a programme around a difficult target? Our scientific team will help you choose the right discovery and engineering strategy for your molecule, before you commit.

Get in touch

Designing a programme around a difficult target? Our scientific team will help you choose the right discovery and engineering strategy for your molecule, before you commit.

Get in touch

Fullspectrum Characterization

fullspectrum-characterization

AnyFormat Manufacturing

anyformat-manufacturing

DeepDesign Engineering

deepdesign-engineering

FunctionInsight Assays

functioninsight-assays

B-Cell Navigator

b-cell-navigator

Solutions

solutions

Platforms & Technologies

platforms-technologies

Why FJBio

why-fjbio

Events & Resources

events-resources

Company

company

About

about

Antibody Discovery

antibody-discovery

Protein Production

protein-production

AtomicLevel Cryo-EM

atomic-level-cryo-em

Biologistics

biologistics

Leadership

leadership

Careers

careers

News & Insights

news-insights

Case Studies

case-studies

Fact Sheets

fact-sheets

CellCraft Solutions

cellcraft-solutions

Cryo-EM

cryo-em

Display Platforms

display-platforms

Events

events

Library Diversity

library-diversity

MultiPath Discovery

multipath-discovery

Publications & Posters

publications-posters

Resources

resources

Screening | Analytics | Data Engines

screening-analytics-data-engines

Single B-Cell Screening

single-b-cell-screening

The Antibody Series Conference

the-antibody-series-conference

Tumbler™

tumbler

Webinars

webinars

White papers

whitepapers

Contact Us

contact-us

Download